New smart drug TQB6411 targets two cancer proteins in early human trial
NCT ID NCT07043751
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose and see if the drug shrinks tumors. It is an early-stage study focused on safety and dosing, not yet a proven treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQB6411 injection (an antibody-drug conjugate that targets EGFR and c-Met proteins on tumor cells to block growth signals and deliver a toxin to kill cancer cells)
- What this could lead to
- If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for advanced cancers that have not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 216 participants, so the drug may prove too toxic or ineffective. It is not yet known if TQB6411 will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anyang Tumor Hospital
NOT_YET_RECRUITINGAnyang, Henan, 455100, China
-
Beijing Friendship Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100050, China
-
Dongguan People's Hospital
NOT_YET_RECRUITINGDongguan, Guangdong, 523059, China
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 519041, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
-
Jining First People's Hospital
NOT_YET_RECRUITINGJining, Shandong, 272002, China
-
Mianyang Central Hospital
NOT_YET_RECRUITINGMianyang, Sichuan, 621000, China
-
Shanghai Jiaotong University School of Medicine, Renji Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
The Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450008, China
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
Zhongnan Hospital Of Wuhan University
NOT_YET_RECRUITINGWuhan, Hubei, 430071, China
-
ZhuJiang Hospital of Southern Medical University
NOT_YET_RECRUITINGGuangdong, Guangdong, 510000, China
-
the Second Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, 410011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Could a personal coach at home boost energy for cancer patients?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Experimental drug combo targets Hard-to-Treat lung cancer